Andreas Busch
Corporate Officer/Principal en ABSCI CORPORATION .
Fortuna: 1 M $ al 29/02/2024
Perfil
Currently, Andreas Eugen Busch is Chief Innovation Officer for Absci Corp.
In the past Dr. Busch was Chief Scientific Officer at Cyclerion Therapeutics, Inc., Chief Scientific Officer & Executive VP at Shire Plc, Executive VP & Head-Global Drug Discovery at Bayer HealthCare AG, Head-Global Drug Discovery at Bayer Pharma AG, Head-Cardiovascular Research at Aventis Pharma AG, Head-Cardiovascular Research at Hoechst Marion Roussel, Inc., Global Head-Cardiovascular Research at Sanofi-Aventis Groupe SA and Professor at Johann Wolfgang Goethe-Universität Frankfurt am Main.
He received a doctorate from Johann Wolfgang Goethe-Universität Frankfurt am Main.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
ABSCI CORPORATION
0.28% | 01/02/2024 | 258 125 ( 0.28% ) | 1 M $ | 29/02/2024 |
Cargos activos de Andreas Busch
Empresas | Cargo | Inicio |
---|---|---|
ABSCI CORPORATION | Corporate Officer/Principal | 04/10/2022 |
Antiguos cargos conocidos de Andreas Busch.
Empresas | Cargo | Fin |
---|---|---|
CENTOGENE N.V. | Director/Board Member | 12/12/2023 |
CYCLERION THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 30/09/2022 |
SHIRE | Chief Tech/Sci/R&D Officer | 01/03/2019 |
Bayer Pharma AG
Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany. | Corporate Officer/Principal | 01/12/2017 |
Aventis Pharma AG | Corporate Officer/Principal | 01/01/2005 |
Formación de Andreas Busch.
Johann Wolfgang Goethe-Universität Frankfurt am Main | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 3 |
---|---|
ABSCI CORPORATION | Health Technology |
CYCLERION THERAPEUTICS, INC. | Health Technology |
CENTOGENE N.V. | Commercial Services |
Empresas privadas | 7 |
---|---|
Shire Plc
Shire Plc Pharmaceuticals: MajorHealth Technology Shire Plc is a biopharmaceutical company, which engages in the research, development, licensing, manufacturing, marketing, distribution, and sale of medicines. Its products include adderall, advate, adynovate, agrylin, antithrombin 3, aralast, bebulin, buccolam, feiba, firazyr, and foznol. The company was founded in 1986 and is headquartered in Dublin, Ireland. | Health Technology |
Bayer HealthCare AG
Bayer HealthCare AG Pharmaceuticals: MajorHealth Technology Bayer HealthCare AG provides healthcare, agriculture, plastics and chemical products. It is an independent company comprising five divisions: Animal Health, Consumer Care, Diabetes Care, Diagnostics and Pharmaceuticals. The company covers the fields of animal health, genetically produced medicines, over the counter products, diagnostic products and prescription drugs. The company is headquartered in Leverkusen, Germany. | Health Technology |
Bayer Pharma AG
Bayer Pharma AG Pharmaceuticals: MajorHealth Technology Bayer Pharma AG engages in the development and production of prescription drugs for the treatment of cardiovascular diseases and women's illnesses, as well as special therapy in the areas of oncology, hematology, and ophthalmology. It also offers medical equipment used in diagnostic imaging with applications in the field of radiology. The company was founded on March 9, 1965 and is headquartered in Berlin, Germany. | Health Technology |
Aventis Pharma AG | |
Hoechst Marion Roussel, Inc. | |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | Commercial Services |
Sanofi-Aventis Groupe SA
Sanofi-Aventis Groupe SA Financial ConglomeratesFinance Sanofi-Aventis Groupe SA operates as a holding company, with interest in the manufacture and distribution of pharmaceutical products. The company was founded on December 19, 1995 and is headquartered in Paris, France. | Finance |